Two Sigma Investments LP Boosts Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Two Sigma Investments LP raised its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 309.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 78,861 shares of the medical research company's stock after acquiring an additional 59,610 shares during the quarter. Two Sigma Investments LP owned about 0.15% of Charles River Laboratories International worth $14,558,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. raised its holdings in Charles River Laboratories International by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company's stock valued at $1,136,938,000 after acquiring an additional 60,497 shares during the period. Wellington Management Group LLP raised its holdings in Charles River Laboratories International by 9.0% during the 4th quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock valued at $752,508,000 after acquiring an additional 335,658 shares during the period. Allspring Global Investments Holdings LLC raised its holdings in Charles River Laboratories International by 2.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock valued at $330,231,000 after acquiring an additional 47,221 shares during the period. Geode Capital Management LLC raised its holdings in Charles River Laboratories International by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company's stock valued at $227,042,000 after acquiring an additional 14,787 shares during the period. Finally, Ariel Investments LLC increased its holdings in shares of Charles River Laboratories International by 18.9% in the fourth quarter. Ariel Investments LLC now owns 1,067,327 shares of the medical research company's stock worth $197,029,000 after purchasing an additional 169,640 shares during the period. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Price Performance

CRL traded down $1.76 during trading on Wednesday, reaching $136.89. The stock had a trading volume of 95,165 shares, compared to its average volume of 989,658. The stock has a market cap of $6.72 billion, a PE ratio of 912.50, a PEG ratio of 4.54 and a beta of 1.50. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $254.15. The business has a 50-day moving average of $130.77 and a 200-day moving average of $162.06.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. During the same period in the prior year, the business posted $2.27 earnings per share. The company's revenue was down 2.7% on a year-over-year basis. As a group, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the company's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the sale, the executive vice president now directly owns 19,513 shares in the company, valued at $2,837,385.33. This represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 1.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on CRL shares. TD Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price objective on the stock in a research report on Wednesday, May 14th. Barclays increased their price objective on Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 8th. Evercore ISI upgraded Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 price objective on the stock in a research report on Thursday, May 8th. Citigroup upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and increased their price objective for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. Finally, Robert W. Baird increased their price objective on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a research report on Thursday, May 8th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of "Hold" and a consensus price target of $171.85.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).